HighTower Advisors’s 9 Meters Biopharma NMTR Stock Holding History

HighTower Advisors’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-950	Closed	-$16K	–	3312
2020 Q4	$16K	Buy	+950	New	+$15.8K	﹤0.01%	2496

Other funds holding NMTR

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

HighTower Advisors's NMTR Position: Q1 2021 in Review

HighTower Advisors sold out of 9 Meters Biopharma (NMTR) in Q1 2021, closing a stake of 950 shares — an estimated $16K sold.

HighTower Advisors first reported a position in NMTR in Q4 2020 and held it in 1 quarter. The position peaked at $16K in Q4 2020. 90 funds tracked by Wall St. Rank hold NMTR as of Q1 2021.

HighTower Advisors reported no remaining 9 Meters Biopharma position as of Q1 2021 after selling out during the quarter.
HighTower Advisors sold 950 9 Meters Biopharma shares in Q1 2021, an estimated $16K.
HighTower Advisors first reported a position in 9 Meters Biopharma in Q4 2020 and held it in 1 quarter.
HighTower Advisors's 9 Meters Biopharma position peaked at $16K in Q4 2020.
90 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q1 2021.

Based on HighTower Advisors's 13F filing for Q1 2021, filed 10 May 2021.